Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases

Journal of Clinical Pharmacology

Volumn 42, Issue 11, 2002, Pages 1228-1236

  Chen, Tianling ^a   Berenson, James ^b   Vescio, Robert ^b   Swift, Regina ^b   Gilchick, Alicia ^b   Goodin, Susan ^c   LoRusso, Patricia ^d   Ma, Peiming ^a   Ravera, Christina ^a   Deckert, Fabienne ^e   Schran, Horst ^a   Seaman, John ^a   Skerjanec, Andrej ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^d WAYNE STATE UNIVERSITY   (United States)

^e NOVARTIS PHARMA K K   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; PEPTIDE; PYRIDINIUM DERIVATIVE; ZOLEDRONIC ACID;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BONE METASTASIS; BONE TURNOVER; BRONCHITIS; CANCER; CLINICAL ARTICLE; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG HALF LIFE; DRUG INFUSION; DRUG SAFETY; FEMALE; FEVER; HUMAN; HYPOKALEMIA; KIDNEY DYSFUNCTION; MALE; MYALGIA; OSTEOLYSIS; PHARMACODYNAMICS; PNEUMONIA; RADIOIMMUNOASSAY; URINARY EXCRETION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BONE NEOPLASMS; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; TIME FACTORS;

EID: 18644373689     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127002762491316     Document Type: Article

References (20)

1. Lin JH: Bisphosphonates: A review of their pharmacokinetic properties. Bone 1996;18:75-85.
2. Green JR, Miiller K, Jaeggi KA: Preclinical of CGP 42'446, a potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994;9:745-751.
3. Green J, Seltenmeyer Y, Jaeggi K, Wilder L: Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. Pharmacol Toxicol 1997;80:225-230.
4. Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, et al: Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19:558-567.
5. Berenson JR, Vescio R, Rosen LS, et al: A phase I dose-dose ranging trial of monthly infusion of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res 2001;7:478-485.
6. Berenson JR, Vescio R, Henick K, et al: A phase 1, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer 2001;91:144-154.
7. Berenson J, Rosen L, Howell A, et al: Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001;91:1191-1200.
8. Arden-Cordone M, Siris E, Lyles K, et al: Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone. Calcif Tissue Int 1997;60:415-418.
9. Rosen L, Gordon D, Kaminski M, et al: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 2001;7(5):377-387.
10. Saad F, Gleason D, Murray R, et al: Zoledronic acid reduces skeletal complications in patients with hormone-refractory prostate carcinoma metastatic to bone: A randomized, placebo-controlled trial. Submitted to J Nat Cancer Inst.
11. Rosen L, Gordon D, Tchekmedyian S, et al: Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double blind, randomized comparative trial. Submitted to J Clin Oncol.
12. Legay F, Gauron S, Deckert F, Gosset G, Pfaar U, Ravera C, Wiegand H, Schran H: Development and validation of a highly sensitive radioimmunoassay for zoledronic acid, a new potent heterocyclic bisphosphonate in human serum, plasma and urine. J Pharm Biomed Anal: in press.
13. Cockroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
14. Kessler M, Grunfeld J, Lascombes F, Necciari J: Pharmacokinetics of tiludronate in patients with chronic severe renal failure. J Bone Miner Res 1996;11:S347.
15. O'Rourke NP, McCloskey EV, Neugebauer G, Kanis JA: Renal and nonrenal clearance of clodronate in patients with malignancy and renal impairment. Drug Invest 1994;7:26-33.
16. Berenson JR, Rosen L, Vescio R, Lau HS, Woo M, Sioufi A, Kowalski MO, Knight RD, Seaman JJ: Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol 1997;37:285-290.
17. Mitchell DY, Peter JVSt, Eusebio RA, Pallone KA, Kelly SC, Russell DA, et al: Effect of renal function on risedronate pharmacokinetics after a single oral dose. Br J Clin Pharmacol 1999;49:215-222.
18. Leyvraz S, Hess U, Flesch G, Bauer J, Hauffe S, Ford JM, Burckhardt P: Pharmacokinetics of pamidronate in patients with bone metastases. J Natl Cancer Inst 1992;84:788-792.
19. Kautiainen S, Luurila S, Ylitalo P, Ylitalo R: Transformation of bisphosphonates into insoluble material in human blood in vitro. Methods Find Exp Clin Pharmacol 1998;20(4):289-295.
20. Kanis J, Preston C, Yates J, et al: Effects of intravenous diphosphonates on renal function. Lancet 1983;1:1328.